Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate that is in Phase Ib/IIa trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the clinical setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone646-661-7661
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableNot Optionable
Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions
What is Ovid Therapeutics' stock symbol?
Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."
How were Ovid Therapeutics' earnings last quarter?
Ovid Therapeutics Inc (NASDAQ:OVID) released its earnings results on Thursday, March, 7th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.03. View Ovid Therapeutics' Earnings History.
When is Ovid Therapeutics' next earnings date?
What price target have analysts set for OVID?
5 analysts have issued 12 month price targets for Ovid Therapeutics' stock. Their predictions range from $10.00 to $27.00. On average, they expect Ovid Therapeutics' share price to reach $15.50 in the next twelve months. This suggests a possible upside of 694.9% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics.
What is the consensus analysts' recommendation for Ovid Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics.
What are Wall Street analysts saying about Ovid Therapeutics stock?
Here are some recent quotes from research analysts about Ovid Therapeutics stock:
- 1. According to Zacks Investment Research, "Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States. " (3/13/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $10 PT on OVID. We view recent P2 Angelman data with OV101 as at least provocative & supportive of efficacy sufficient to warrant further evaluation. We believe the efficacy signal suggests clinical value sufficient for positive outcomes in not only future Angelman trials but also FXS and other neurodevelopmental disorders with similar neuropsych symptoms. The co.’s second asset, OV935, targeted for developmental epileptic encephalopathies (DEE), provides The Disclosure Section may be found on pages 4 – 5.potential upside to our valuation and we look forward to PoC data in the near-term to increase visibility on the potential of this asset." (12/6/2018)
Has Ovid Therapeutics been receiving favorable news coverage?
Press coverage about OVID stock has been trending neutral this week, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ovid Therapeutics earned a news impact score of 0.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Ovid Therapeutics' key competitors?
Some companies that are related to Ovid Therapeutics include TAIWAN LIPOSOME/S (TLC), ADMA Biologics (ADMA), Rafael (RFL), REDHILL BIOPHAR/S (RDHL), Menlo Therapeutics (MNLO), Pieris Pharmaceuticals (PIRS), Cynata Therapeutics (CYP), Arix Bioscience (ARIX), Northwest Biotherapeutics (NWBO), BEXIMCO PHARMAC/S GDR REGS (BXP), Spring Bank Pharmaceuticals (SBPH), Aratana Therapeutics (PETX), Millendo Therapeutics (MLND), Pacific Smiles Group (PSQ) and Axovant Sciences (AXON).
What other stocks do shareholders of Ovid Therapeutics own?
Who are Ovid Therapeutics' key executives?
Ovid Therapeutics' management team includes the folowing people:
- Dr. Jeremy Max Levin, Chairman & CEO (Age 66)
- Dr. Matthew J. During, Founder, Pres, Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 62)
- Ms. Lora Pike, Sr. Director of Investor Relations & PR
- Ms. Ana C. Ward Esq., M.S., M.B.A., Sr. VP, Gen. Counsel & Sec. (Age 50)
- Ms. Suzanne K. Wakamoto SPHR, SHRM-SCP, Sr. VP of HR
When did Ovid Therapeutics IPO?
(OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.
Who are Ovid Therapeutics' major shareholders?
Ovid Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.74%), Tekla Capital Management LLC (2.02%), Geode Capital Management LLC (0.39%), Geode Capital Management LLC (0.39%), Dimensional Fund Advisors LP (0.35%) and Dimensional Fund Advisors LP (0.35%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin and Karen Bernstein. View Institutional Ownership Trends for Ovid Therapeutics.
Which institutional investors are selling Ovid Therapeutics stock?
Which institutional investors are buying Ovid Therapeutics stock?
OVID stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, SG Americas Securities LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Geode Capital Management LLC, Geode Capital Management LLC and Rhumbline Advisers. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin and Karen Bernstein. View Insider Buying and Selling for Ovid Therapeutics.
How do I buy shares of Ovid Therapeutics?
Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ovid Therapeutics' stock price today?
One share of OVID stock can currently be purchased for approximately $1.95.
How big of a company is Ovid Therapeutics?
Ovid Therapeutics has a market capitalization of $75.36 million. The company earns $-51,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis.
What is Ovid Therapeutics' official website?
How can I contact Ovid Therapeutics?
Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]
MarketBeat Community Rating for Ovid Therapeutics (NASDAQ OVID)
MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe OVID will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVID will underperform the S&P 500 over the long term. You may vote once every thirty days.
